These data suggest that an upfront co-treatment strategy with an EZH2 inhibitor could prevent the emergence of resistance to HER2-targeted therapy, which is believed to impair the viability of residual drug-tolerant subclones, thus diminishing the recurrence of therapy-refractory cancer cells. This evidence concerns the gene ERBB2 and cancer.